NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According to the announcement, POAI’s previously announced offering closed with 2,200,000 shares of common stock being sold, at a price of $1.00 per share. The gross proceeds for POAI was $2.2 million, with the company planning to use the funds for working capital purposes. Placement agent fees…







